Neurocrine Biosciences, Inc. (0K6R.L)
USD 109.75
(1.72%)
USD 109.75
(1.72%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 428.4 Million USD | 62.95% |
| 2022 | 262.9 Million USD | -40.3% |
| 2021 | 440.4 Million USD | 6.82% |
| 2020 | 412.3 Million USD | -16.79% |
| 2019 | 495.5 Million USD | 27.54% |
| 2018 | 388.49 Million USD | 5.11% |
| 2017 | 369.61 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 11.53 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 1.48 Million USD | -97.23% |
| 2006 | 53.64 Million USD | -9.7% |
| 2005 | 59.4 Million USD | -10.17% |
| 2004 | 66.12 Million USD | 81.5% |
| 2003 | 36.43 Million USD | 359.14% |
| 2002 | 7.93 Million USD | 39.53% |
| 2001 | 5.68 Million USD | 46.95% |
| 2000 | 3.87 Million USD | 24.84% |
| 1999 | 3.1 Million USD | 3.33% |
| 1998 | 3 Million USD | 87.5% |
| 1997 | 1.6 Million USD | 0.0% |
| 1996 | 1.6 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 546.9 Million USD | 27.66% |
| 2024 Q2 | 291.6 Million USD | -46.68% |
| 2024 Q3 | 251.4 Million USD | -13.79% |
| 2023 Q3 | 255.8 Million USD | -1.16% |
| 2023 Q1 | 259.9 Million USD | -1.14% |
| 2023 Q4 | 428.4 Million USD | 67.47% |
| 2023 Q2 | 258.8 Million USD | -0.42% |
| 2023 FY | 428.4 Million USD | 62.95% |
| 2022 Q2 | 268.6 Million USD | -44.06% |
| 2022 Q4 | 262.9 Million USD | -1.09% |
| 2022 Q1 | 480.2 Million USD | 9.04% |
| 2022 FY | 262.9 Million USD | -40.3% |
| 2022 Q3 | 265.8 Million USD | -1.04% |
| 2021 FY | 440.4 Million USD | 6.82% |
| 2021 Q1 | 429.5 Million USD | 4.17% |
| 2021 Q2 | 435.3 Million USD | 1.35% |
| 2021 Q3 | 437.1 Million USD | 0.41% |
| 2021 Q4 | 440.4 Million USD | 0.75% |
| 2020 Q4 | 412.3 Million USD | -18.84% |
| 2020 FY | 412.3 Million USD | -16.79% |
| 2020 Q3 | 508 Million USD | 0.83% |
| 2020 Q2 | 503.8 Million USD | 0.82% |
| 2020 Q1 | 499.7 Million USD | 0.85% |
| 2019 Q1 | 460.58 Million USD | 18.56% |
| 2019 Q2 | 464.65 Million USD | 0.88% |
| 2019 Q3 | 478.07 Million USD | 2.89% |
| 2019 Q4 | 495.5 Million USD | 3.65% |
| 2019 FY | 495.5 Million USD | 27.54% |
| 2018 Q4 | 388.49 Million USD | 1.26% |
| 2018 Q1 | 374.2 Million USD | 1.24% |
| 2018 Q2 | 378.88 Million USD | 1.25% |
| 2018 Q3 | 383.64 Million USD | 1.26% |
| 2018 FY | 388.49 Million USD | 5.11% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 369.61 Million USD | 1.23% |
| 2017 Q3 | 365.11 Million USD | 1.23% |
| 2017 Q2 | 360.68 Million USD | 0.0% |
| 2017 FY | 369.61 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | 10.53 Million USD | -8.66% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 8.53 Million USD | -10.57% |
| 2010 Q2 | 9.54 Million USD | -9.39% |
| 2009 Q4 | 11.53 Million USD | -33.26% |
| 2009 Q2 | 18.16 Million USD | -0.3% |
| 2009 FY | 11.53 Million USD | 0.0% |
| 2009 Q1 | 18.21 Million USD | 0.0% |
| 2009 Q3 | 17.27 Million USD | -4.89% |
| 2008 Q3 | 276 Thousand USD | -54.08% |
| 2008 FY | - USD | -100.0% |
| 2008 Q1 | 1.02 Million USD | -31.02% |
| 2008 Q2 | 601 Thousand USD | -41.37% |
| 2008 Q4 | - USD | -100.0% |
| 2007 Q4 | 1.48 Million USD | -97.04% |
| 2007 FY | 1.48 Million USD | -97.23% |
| 2007 Q3 | 50.12 Million USD | -2.1% |
| 2007 Q2 | 51.2 Million USD | -2.29% |
| 2007 Q1 | 52.4 Million USD | -2.31% |
| 2006 Q2 | 56.45 Million USD | -2.59% |
| 2006 FY | 53.64 Million USD | -9.7% |
| 2006 Q4 | 53.64 Million USD | -2.46% |
| 2006 Q1 | 57.95 Million USD | -2.45% |
| 2006 Q3 | 54.99 Million USD | -2.58% |
| 2005 Q3 | 60.99 Million USD | -2.62% |
| 2005 FY | 59.4 Million USD | -10.17% |
| 2005 Q1 | 64.4 Million USD | -2.6% |
| 2005 Q2 | 62.63 Million USD | -2.75% |
| 2005 Q4 | 59.4 Million USD | -2.61% |
| 2004 Q1 | 47.13 Million USD | 29.36% |
| 2004 Q3 | 68.69 Million USD | 16.67% |
| 2004 Q2 | 58.88 Million USD | 24.93% |
| 2004 Q4 | 66.12 Million USD | -3.74% |
| 2004 FY | 66.12 Million USD | 81.5% |
| 2003 FY | 36.43 Million USD | 359.14% |
| 2003 Q3 | 22.52 Million USD | 0.27% |
| 2003 Q2 | 22.46 Million USD | 170.62% |
| 2003 Q1 | 8.3 Million USD | 4.63% |
| 2003 Q4 | 36.43 Million USD | 61.73% |
| 2002 FY | 7.93 Million USD | 39.53% |
| 2002 Q3 | 6.68 Million USD | 19.64% |
| 2002 Q4 | 7.93 Million USD | 18.63% |
| 2002 Q2 | 5.59 Million USD | 9.31% |
| 2002 Q1 | 5.11 Million USD | -10.06% |
| 2001 Q4 | 5.68 Million USD | 52.22% |
| 2001 FY | 5.68 Million USD | 46.95% |
| 2001 Q1 | 3.52 Million USD | -8.94% |
| 2001 Q2 | 4.16 Million USD | 18.16% |
| 2001 Q3 | 3.73 Million USD | -10.28% |
| 2000 FY | 3.87 Million USD | 24.84% |
| 2000 Q1 | 2.87 Million USD | -7.29% |
| 2000 Q2 | 2.63 Million USD | -8.39% |
| 2000 Q3 | 3.05 Million USD | 16.1% |
| 2000 Q4 | 3.87 Million USD | 26.59% |
| 1999 Q1 | 3.6 Million USD | 20.0% |
| 1999 Q2 | 2.3 Million USD | -36.11% |
| 1999 Q3 | 3.1 Million USD | 34.78% |
| 1999 Q4 | 3.1 Million USD | 0.0% |
| 1999 FY | 3.1 Million USD | 3.33% |
| 1998 Q2 | 1.7 Million USD | 41.67% |
| 1998 Q4 | 3 Million USD | -6.25% |
| 1998 Q1 | 1.2 Million USD | -25.0% |
| 1998 FY | 3 Million USD | 87.5% |
| 1998 Q3 | 3.2 Million USD | 88.24% |
| 1997 Q2 | 1.2 Million USD | 0.0% |
| 1997 Q4 | 1.6 Million USD | 45.45% |
| 1997 Q1 | 1.2 Million USD | -25.0% |
| 1997 FY | 1.6 Million USD | 0.0% |
| 1997 Q3 | 1.1 Million USD | -8.33% |
| 1996 Q4 | 1.6 Million USD | 23.08% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 FY | 1.6 Million USD | 0.0% |
| 1996 Q3 | 1.3 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| uniQure N.V. | 138.4 Million USD | -209.517% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -9631.94% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -13836.239% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -651.737% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -640.254% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -892.425% |
| Imunon, Inc. | 1.13 Million USD | -37502.267% |
| Dynavax Technologies Corporation | 256.91 Million USD | -66.748% |
| Editas Medicine, Inc. | 36.53 Million USD | -1072.542% |
| FibroGen, Inc. | 170.45 Million USD | -151.327% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -42740.0% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1079.418% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 69.33% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -931.618% |
| Verastem, Inc. | 41.55 Million USD | -930.873% |
| Zoetis Inc. | 6.8 Billion USD | 93.703% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 47.006% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -1024.291% |
| Homology Medicines, Inc. | 44.05 Million USD | -872.443% |
| Nektar Therapeutics | 230.4 Million USD | -85.937% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -33900.0% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -1487.255% |
| Perrigo Company plc | 4.07 Billion USD | 89.483% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 20.806% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 95.516% |
| Illumina, Inc. | 2.26 Billion USD | 81.061% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 98.773% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 96.99% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -146.557% |
| Waters Corporation | 2.35 Billion USD | 81.813% |
| Biogen Inc. | 7.33 Billion USD | 94.162% |
| Evolus, Inc. | 126.54 Million USD | -238.533% |
| Adicet Bio, Inc. | 17.7 Million USD | -2319.929% |
| bluebird bio, Inc. | 330.32 Million USD | -29.69% |
| Geron Corporation | 85.89 Million USD | -398.725% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 82.135% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 3.743% |
| Myriad Genetics, Inc. | 145 Million USD | -195.448% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -271.404% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 80.238% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -1951.308% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 62.218% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 84.15% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 84.336% |
| OPKO Health, Inc. | 326.56 Million USD | -31.184% |
| Exelixis, Inc. | 189.94 Million USD | -125.54% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -283608.609% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -129.863% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 70.527% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 71.426% |
| Blueprint Medicines Corporation | 774.12 Million USD | 44.66% |
| Insmed Incorporated | 1.2 Billion USD | 64.418% |
| TG Therapeutics, Inc. | 110.79 Million USD | -286.66% |
| Incyte Corporation | 38.28 Million USD | -1018.918% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 51.179% |